Detail akcie Iridex Corp online

Business Summary: IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Financial Summary: BRIEF: For the fiscal year ended 30 December 2023, IRIDEX Corp revenues decreased 9% to $51.9M. Net loss increased 27% to $9.6M. Revenues reflect United States segment decrease of 11% to $26.1M, Rest of the Americas segment decrease of 33% to $2.1M. Higher net loss reflects Selling expenses increase of 17% to $7.9M (expense), Stock-based Compensation in R&D increase of 40% to $217K (expense).